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Klotho is an antiaging substance with pleiotropic actions
including regulation of mineral metabolism. It is highly
expressed in the kidney and is present in the circulation and
urine but its role in acute kidney injury (AKI) is unknown. We
found that ischemia–reperfusion injury (IRI) in rodents
reduced Klotho in the kidneys, urine, and blood, all of which
were restored upon recovery. Reduction in kidney and
plasma Klotho levels were earlier than that of neutrophil
gelatinase-associated lipocalin (NGAL), a known biomarker of
kidney injury. Patients with AKI were found to have drastic
reductions in urinary Klotho. To examine whether Klotho has
a pathogenic role, we induced IRI in mice with different
endogenous Klotho levels ranging from heterozygous Klotho
haploinsufficient, to wild-type (WT), to transgenic mice
overexpressing Klotho. Klotho levels in AKI were lower in
haploinsufficient and higher in transgenic compared with WT
mice. The haploinsufficient mice had more extensive
functional and histological alterations compared with WT
mice, whereas these changes were milder in overexpressing
transgenic mice, implying that Klotho is renoprotective. Rats
with AKI given recombinant Klotho had higher Klotho
protein, less kidney damage, and lower NGAL than rats with
AKI given vehicle. Hence, AKI is a state of acute reversible
Klotho deficiency, low Klotho exacerbates kidney injury and
its restoration attenuates renal damage and promotes
recovery from AKI. Thus, endogenous Klotho not only serves
as an early biomarker for AKI but also functions as a
renoprotective factor with therapeutic potential.
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Acute kidney injury (AKI) is a formidable clinical problem
resulting primarily from ischemia or nephrotoxins, with
outcomes ranging from full recovery to the development of
chronic kidney disease with dialysis dependence, or death.1,2
Epidemiological data estimates an annual incidence of
22–620 per million with overall immediate mortality of up
to 23 and 79%.3 This unacceptably high mortality has
improved only modestly despite advances in our under-
standing of the pathogenesis and improvements in dialysis.
Even if patients survive the acute insult, long-term prognosis
after AKI is still far from optimal,4 with survival rates
projected as 46–74, 55–73, 57–65, and 65–70% at 90 days,
6 months, 1 year, and 5 years, respectively.5 The annual
incidence of end-stage renal disease from AKI survivors has
increased from 0.4 to 4.9 per 100,000 between 1998 and
2002.6 Patients who had an episode of AKI are at higher risk
for the development of chronic kidney disease.7 The poor
outcome can be attributable to both delayed diagnosis due to
the lack of sensitive and specific early biomarkers and limited
efficacious specific therapies.
Klotho was originally identified as an aging suppressor
gene8,9 with pleiotropic functions. It encodes a single-pass
transmembrane protein and is expressed in the kidney, where
it functions as a coreceptor for fibroblast growth factor-23
(FGF23) and has a critical role in phosphate metabolism.10–12
The extracellular domain of Klotho is cleaved on the cell
surface by membrane-anchored proteases, and released into
blood,13–15 urine,16,17 and cerebrospinal fluid.15 Secreted
Klotho protein has multiple functions distinct from those
of membrane Klotho, including regulation of multiple ion
channels16–19 and oxidative stress.20 Recent studies demon-
strated that Klotho might also be renoprotective in chronic
glomerulonephritis.21 Data on Klotho in AKI are limited.
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One study showed that renal Klotho mRNA and protein is
decreased 1 day after ischemia reperfusion and adenoviral
delivery of Klotho led to modest 15% decrease in serum
creatinine (Cr) concentration after ischemia.22 It will be
important to know whether there is a systemic deficiency of
Klotho in AKI and what is the time profile of the decrease.
Furthermore, whether lower Klotho expression makes
animals more susceptible to ischemic injury has not been
addressed. This study was conducted to definitively address
four unanswered questions: (1) Is AKI a temporary state of
systemic Klotho deficiency? (2) Is decreased Klotho in blood
and urine an early biomarker of AKI? (3) Do Klotho express-
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Figure 1 |Characterization of acute kidney injury (AKI) in rats. AKI and Sham rats were killed at 1, 2, and 7 days after
ischemia–reperfusion injury (IRI) and blood and urine were collected. (a) PCr, plasma creatinine; (b) ClCr, creatinine clearance; (c) U/Posm,
urine-to-plasma osmolality; and (d) FENa, fractional excretion of Na
þ . Values are expressed as means±s.e.m. of six rats in each group.
Statistical differences for a, b, c, and d on days 0, 1, 2, and 7 were analyzed by analysis of variance (ANOVA) followed by
Student–Newman–Keuls test, and significant differences were accepted when *Po0.05, **Po0.01 vs Sham group; #Po0.05; ##Po0.01 vs AKI
rats at day 0. Kidneys were harvested for hematoxylin and eosin (H and E) staining (e, top panel) on days 1, 2, and 7 after IRI. Kidney
histological scores (e, bottom panel) from H and E staining (e, top panel) were obtained by a renal pathologist blinded to the experimental
conditions using a semi-quantitative pathological scoring system as described in Methods section. Scores are expressed as mean±s.e. of
four samples in each group. Statistical differences were analyzed by ANOVA followed by Student–Newman–Keuls test, and significant
differences were accepted when Po0.05 or less between two groups. A, AKI; S, Sham.
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ion levels affect the outcome and course of AKI?
Most importantly, (4) Does Klotho administration ameliorate
kidney damage in AKI and/or promote recovery from AKI?
RESULTS
AKI from IRI is an acute state of Klotho deficiency
After bilateral renal arterial occlusion (30 min in mice;
40 min in rats), all animals showed at least two- to threefold
increase in blood urea nitrogen and/or plasma Cr above
baseline (Figure 1, Table 1) with no mortality before
termination of study (o10 days after ischemia–reperfusion
injury (IRI)). Plasma Cr peaked on day 1, started to decline
on day 2, but still remained higher on day 7 compared with
Sham rats (Figure 1a). Endogenous Cr clearance dropped
dramatically on day 1 and started to recover on day 2,
(Figure 1b). IRI also affected renal tubular function as
evident by the reduced urinary osmolality and increased
fractional excretion of Na (Figure 1c and d). Histology on day
2 showed widespread protein casts in dilated tubules (Figure
1e). Proximal tubular cells lost their brush border membrane
and nuclei, and became flat and eosinophilic, compatible
with cell necrosis. There were erythrocyte congestion and
some intrarenal extravasation in the medulla.
The kidney has the highest expression of Klotho among all
organs in the rodent8,14 and is likely a major source of
circulating Klotho. Both Klotho protein (Figure 2a and b)
and mRNA (Figure 2c) were reduced in kidneys of AKI rats
on days 1 and 2. Previous studies never examined Klotho
levels in plasma or urine in AKI. Similar to the low
erythropoietin state in blood in acute kidney diseases from
a variety of insults,23 we found substantial decrease in both
plasma and urine Klotho protein in AKI rats, suggesting a
state of ‘pan-Klotho-deficiency’ (Figure 2d and e). By the
seventh day, Klotho in the kidney, plasma, and urine of AKI
rats returned to the levels comparable with Sham rats (Figure
2a–e), indicating that AKI induces acute and transient
systemic Klotho deficiency. Because the human plasma
Klotho assay was not ready and access to kidney biopsies
were understandably limited at the time of the study, only
urine Klotho levels were measured. Fresh urine samples of
17 AKI patients (Table 2) had notably lower Klotho protein
than normal healthy volunteers (Figure 2f, Supplementary
Figure S1 online, Table 3).
Klotho deficiency is an early biomarker for AKI induced by IRI
To explore the time course of changes in Klotho, we
measured plasma and renal Klotho in very early stages
(1, 3, 5, and 24 h post-IRI) of AKI. Plasma Cr was slightly
increased at 5 h, which eventually reached statistical sig-
nificance after 24 h (Supplementary Figure S2A online). Mild
alteration of kidney morphology was detectable at 5 h post-
reperfusion with slight degeneration in proximal tubules and
mild hemorrhage in the interstitium at 5 h. After 24 h, there
were marked necrosis and loss of brush border membrane in
proximal tubules with higher kidney pathological scores
(Supplementary Figure S2B,C online). Interestingly, Klotho
levels in plasma and kidney were moderately increased at 1 h
post-reperfusion, but immediately and sustainably decreased
after 3 h (Figure 3a and b and Supplementary Figure S2D
online). Thus, changes in blood and renal Klotho levels
preceded changes in plasma Cr or kidney histology (Figure 3
and Supplementary Figure S2A-D online). Plasma and
kidney neutrophil gelatinase-associated lipocalin (NGAL)
levels started to rise 5 h after reperfusion (Figure 3c and d and
Supplementary Figure S2E online). Thus, Klotho might be
one of the earliest biomarkers for kidney injury, at least for
AKI induced by IRI.
Klotho deficiency accentuates and Klotho overexpression
attenuates AKI
If AKI is a state of acute Klotho deficiency, the logical and
most critical question is whether this is merely a marker of
renal damage or a contributor to renal dysfunction. To
address this, we induced AKI in mice with three different
Klotho expression levels. It was impossible to induce
experimental AKI in the homozygous knockout mice (Kl/)
because of 100% surgical mortality so we compared Klotho
haploinsufficient (Klþ /) mice with their wild-type (WT)
counterparts. Klþ / mice had lower levels of Klotho protein
in the plasma, kidney, and urine at baseline, which became
undetectable after AKI (Figure 4a–d). Klþ / mice developed
more severe renal dysfunction (Table 4) and more extensive
histological abnormalities (Supplementary Figure S3C,D
online), such as tubular casts, tubule dilation, loss of brush
border membrane, and interstitial hemorrhage than WTmice
(Supplementary Figure S3G,H online).
Transgenic Klotho-overexpressing (Tg-Kl) mice had
higher renal (Figure 4a and b), plasma (Figure 4c), and
urinary Klotho (Figure 4d) at baseline. Upon induction of
ischemia–reperfusion, Klotho protein decreased but still
maintained levels comparable with those in Sham WT mice
(Figure 4a–d). Tg-Kl mice were more resistant to injury
(Table 5) with fewer casts in the renal tubules and almost
intact brush border membrane in proximal tubules (Supple-
mentary Figure S3K,L online) compared with WT AKI mice
(Supplementary Figure S3G,H online). Kidney histological
scores were significantly lower in AKI Tg-Kl mice and higher
Table 1 | Plasma and urine chemistry of AKI rats on day 2
after IRI
Sham AKI
Body weight (g) 323.1±10.2 331.5±11.5
Cr (mg/dl) 0.43±0.08 2.31±0.45**
BUN (mg/dl) 27.3±7.3 104.1±13.5**
ClCr (ml/min/Kg) 1.20±0.23 0.29±0.05*
U/P osmolality 5.32±1.03 2.47±0.55**
FENa (%) 0.11±0.03 0.62±0.11*
Abbreviations: AKI, acute kidney injury; BUN, blood urea nitrogen; Cr, creatinine; ClCr,
Cr clearance; FENa, fractional excretion of Na; IRI, ischemia–reperfusion injury; U/P,
urine-to-plasma.
Data are represented as means±s.e.m.; n=4. Significant differences were accepted
when *Po0.05, **Po0.01 vs Sham; by unpaired Student’s t-test.
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in AKI Klþ / mice compared with their WT counterparts
(Figure 4e). The histological findings in Tg-Kl mice are
similar to the results from one previous study, in which
Klotho was increased using viral gene delivery.22,24 It is
noteworthy that Tg-Kl mice at baseline did not have higher
Cr clearance than Sham WT mice (Table 5), so the beneficial
effect of Klotho overexpression on renal IRI is not simply a
‘glomerular filtration rate enhancing’ effect.
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Figure 2 |Klotho levels in acute kidney injury (AKI) rats from 1 to 7 days post-ischemia–reperfusion injury (IRI). (a) Representative
immunohistochemistry for Klotho protein in kidneys from three rats in each group on days 1, 2, and 7 post-IRI. Four mm frozen kidney
sections were stained for Klotho with rabbit anti-Klotho (KMDC)49 (1/50 dilution) and for b-actin. (b) Representative immunoblot (30 mg
protein per lane) for Klotho in total kidney lysate from AKI and Sham rats at days 1, 2, and 7 after IRI with rat anti-Klotho antibody
(KM2076).49 The upper panel is a representative blot. The lower panel is a summary of densitometric analysis of all samples from Sham and
AKI rats. (c) Klotho transcripts in kidney. One mg of total RNA from kidneys of AKI and Sham rats on day 1, 2, and 7 after IRI was used to
generate complementary DNA using oligo-dT primers and real-time PCR for Klotho and cyclophilin was performed. Quantification of Klotho
transcripts was calculated as described in Methods section. (d) Representative immunoblot for immunoprecipitated plasma Klotho. One
hundred ml of heparinized blood from AKI and Sham rats on days 1, 2, and 7 were immunoprecipitated (IP) with 4 ml of rabbit anti-Klotho
antibody (KMDC), and the immune complex was immunoblotted with rat anti-Klotho antibody (KM2076, 1/3000 dilution). The band of
immunoglobulin heavy chain (IgG-HC) was shown for IP control. The upper panel is a representative blot. The lower panel is summary of
densitometric analysis of all samples from Sham and AKI rats. Values are expressed as means±s.e.m. of six rats in each group. Statistical
differences were analyzed by analysis of variance (ANOVA) followed by Student–Newman–Keuls test and significant differences were
appreciated when **Po0.01 vs Sham group; #Po0.05; ##Po0.01 vs AKI group at day 1; dPo0.05; ddPo0.01 vs AKI group at day 2.
(e) Representative immunoblot for urinary Klotho from rats a volume of fresh urine containing 10 mg of creatinine was immunoblotted with
rat anti-Klotho antibody (KM2076). Lane 1 was loaded with 20 fmoles of recombinant mouse Klotho protein (rMKl). The top panel is a
representative blot for Klotho in urine samples of AKI rats at days 0, 1, 2, and 7. The bottom panel is summary of densitometric
quantification of data from immunoblot. (f) Representative immunoblot for Klotho protein in urine samples of normal subjects (open circle)
and of AKI patients (closed circle). A volume of concentrated human urine containing 50 mg of creatinine was loaded. Top panel shows
membrane blotted with rat anti-Klotho antibody. Values for individual subjects are shown in bottom panel. Values are expressed as
means±s.e.m. of six rats in each group. Statistical differences for b, c, and e were analyzed by ANOVA followed by Student–Newman–Keuls
test, and significant differences were accepted when Po0.05 or less between two groups.
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Klotho administration post-ischemia rescues rat kidney from AKI
In clinical settings, practitioners rarely have the chance to
anticipate AKI but are usually confronted with the syndrome
after established injury. Thus, any meaningful therapy has to
be efficacious when given after AKI develops. We next tested
whether administration of Klotho after AKI may still exert
therapeutic benefits in AKI. We administered recombinant
Klotho protein (soluble extracellular domain of Klotho
protein at 0.01 mg/kg body weight) intraperitoneally 30 min
after the ischemic injury. Single bolus injection of Klotho
protein 30 min post-injury was effective in attenuating AKI
(Figure 5a–f). Klotho treatment post-IRI significantly
lessened the elevation of plasma Cr and blood urea nitrogen,
and decline in Cr clearance (Figure 5a–c) on first 2 days
compared with vehicle injection. The abnormal blood and
urinary parameters returned to near basal levels (Figure 5a–c)
after 7 days of IRI.
On ad libitum water consumption, AKI rats were oliguric
on day 1 and 2, and polyuric on day 7 compared with the
Sham group, whereas AKI-Klotho rats had milder oliguria on
day 1 and less polyuria on day 7 (Figure 5d). The defect in
urinary concentrating ability was also ameliorated by Klotho
treatment (Figure 5e).
Kidney histology showed milder damage in Klotho-treated
rats compared with vehicle-treated rats (Supplementary
Figure S4 online). On day 7, the kidney of vehicle-treated
rats started to regenerate, but still had numerous dilated renal
tubules and granular casts. In contrast, Klotho-treated rats
had near-normal kidney morphology (Supplementary
Figure S4 online) by day 7. The histopathological scores for
Klotho-treated AKI rats were significantly lower than the
vehicle-treated AKI rats, but higher than sham rats (Figure
5f) on day 1. The pathological score decreased with time in
the vehicle-treated AKI rat, but the score declined more
rapidly in Klotho-treated AKI rats (Figure 5f), suggesting
Klotho may also enhance kidney recovery from AKI.
NGAL protein (Figure 6a; Supplementary Figure S5A
online) and mRNA (Figure 6b) were upregulated in the
kidneys with AKI, but the increase was much less in Klotho-
treated rats. As NGAL has been considered as a real-time
indicator of active kidney damage,25–27 these results suggest
that Klotho treatment led to less severe damage by IRI.
However, an interesting finding was that Klotho significantly
upregulated endogenous renal NGAL mRNA and protein
expression in the Sham animals in the absence of ischemia
(Figure 6a and b). NGAL has been proposed as a
renoprotective substance and administration of exogenous
NGAL attenuates kidney damage and improves renal
function induced by ischemia.28 Augmentation of endogen-
ous NGAL expression in kidney by Klotho may be one
potential mechanism whereby Klotho confers protective
effect against ischemic renal injury.
We examined renal Klotho protein levels after adminis-
tration of exogenous Klotho. AKI rats treated with Klotho
protein had milder decline in Klotho protein content in the
Table 2 | Klotho protein in urine of AKI patients
Normal subject AKI
Age (year) 47.7±3.1 44.8±4.3
(n) (14) (17)
Gender (F/M) 7/7 7/10
Cr (mg/dl)# 0.73±0.05 3.76±0.58**
Urinary Klotho (pmoles/l) 20.66±1.81 2.52±0.76**
Urinary Klotho/Cr (fmoles/mg) 25.38±4.08 4.85±1.69**
Abbreviations: AKI, acute kidney injury; Cr, creatinine.
#Blood creatinine when AKI patients’ urines were collected for urinary Klotho
determination. Significant differences were accepted when *Po0.05, **Po0.01 vs
normal subjects by unpaired Student’s t-test.
Table 3 | Clinical profile and urinary Klotho protein in AKI patients
Potential contributors to AKI
Scr
(mg/dl) Klotho in urine Outcome
ID
Age
(years) Gender
Pre-
renal Sepsis
Nephro-
toxin Lupus
Hyper-
tension DN HUS OU
Solitary
kidney CKD
Graft
rejection
Pre-
eclamp-
sia HRS
Base-
line Peak
Klotho
(pmoles/l)
Klotho/
Cr
(fmoles/mg)
Short
term o3
months
Scr
(mg/dl)
IN-1 78 F + 0.89 2.73 1.31 1.28 FR 0.87
IN-2 41 M + 1.17 3.77 5.90 10.41 FR 0.84
IN-3 53 M + 1.10 2.43 3.34 4.96 FR 0.97
IN-4 34 M + 0.96 1.79 10.27 19.75 PR 1.49
IN-5 21 F + 1.0 3.17 0 0 Death 4.67
IN-6 37 F + 0.36 2.62 6.87 20.09 FR 0.62
IN-7 68 M + 0.75 5.57 4.9 3.2 PR 1.33
IN-8 68 M + 0.49 5.58 0.15 0.12 FR 0.81
IN-9 55 M + + 1.05 9.76 2.1 2.10 PR 4.78
IN-10 22 F + 0.68 1.71 0.10 0.07 Death 0.84
IN-11 55 F + 1.2 2.25 0.30 0.60 Death 3.5
IN-12 20 F + + 0.89 1.38 7.34 9.38 PR 1.29
IN-13 60 M + + + + + 1.98 4.70 0 0 Death 2.90
IN-14 49 F + 0.80 4.05 0 0 CKD4 3.64
IN-15 28 M + + 2.20 7.89 0.28 0.56 CKD4 4.5
IN-16 48 M + 0.77 1.92 2.97 6.51 Death 2.86
IN-17 55 M + 1.10 1.86 7.9 12.8 FR 0.98
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; DN, diabetic nephropathy; FR, full recovery; HRS, hepatorenal syndrome; HUS, hemolytic uremic
syndrome; OU, obstructive uropathy; PR, partial recovery; Scr, serum creatinine.
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kidney (Figure 6c; Supplementary Figure S5B online)
compared with AKI rats without Klotho treatment on day
1 and 2. This can potentially stem from renal accumulation of
injected Klotho protein and/or preservation of endogenous
Klotho expression caused by injected exogenous Klotho. It
should be noted that Sham rats that received exogenous
Klotho also had higher Klotho protein levels (Figure 6c), but
lower mRNA expression (Supplementary Figure S5C online)
in the kidneys compared with Sham rats given vehicle in the
absence of ischemia.
To determine whether delayed administration of Klotho
exerts renoprotective effects in AKI, we injected Klotho
intraperitoneally into rats 60 min after IRI and compared
them with those treated 30 min after IRI. Delayed Klotho
treatment blunted the increase in blood Cr (Supplementary
Figure S6A online) and decrease in Cr clearance (Supple-
mentary Figure S6B online), and decreased proteinuria
(Supplementary Figure S6C online). The degree of oliguria
on the first and second day and the degree of polyuria at
seventh day were also decreased (Supplementary Figure S6D
online). Moreover, the increase in fractional excretion of Na
was also diminished by later Klotho treatment (Supplemen-
tary Figure S6E online). The alleviation of histological scores
(Supplementary Figure S6F online) was similar to those of
physiological parameters (Supplementary Figure S6A–E
online). Therefore, Klotho treatment at 60 min post-injury
was still effective but the renoprotection was less efficient
than that of Klotho treatment 30 min post-IRI. Therefore,
early intervention conveys better outcome than delayed
treatment, although the delayed treatment still has the
capacity of renoprotection.
The more abundant renal Klotho protein in Klotho-
treated animals might be of either exogenous or endogenous
in origin because our detection methods do not distinguish
native versus injected Klotho. To test this possibility, we
labeled recombinant Klotho with an infrared tag and injected
it into rats to track its fate. We found substantial levels of
exogenous Klotho protein in the blood circulation within
5 min after a single intravenous bolus (Figure 6d), which
diminished over the next 2 days. Klotho appeared to stay
longer in the blood of AKI rats compared with Sham rats, as
it was still detectable in blood after 48 h. In contrast to
plasma, we only detected traces of injected Klotho in the
urine after 20 min of injection in Sham rats and not in AKI
rats; no exogenous Klotho was recovered in the urine after 24
and 48 h. Kidneys of Sham rats retained the labeled Klotho
up to 2 days (at termination study) (Figure 6e). Kidneys of
AKI rats have more Klotho in the renal cortex compared with
Sham rats. This is compatible with the model in which
exogenously administered Klotho protein can enter and stay
in the kidney, thereby potentially activating protective
pathways supporting its therapeutic potential.
DISCUSSION
The purpose of this study was to (1) determine whether AKI
is an acute and transient state of deficiency in both
membrane and secreted Klotho; (2) determine whether
Klotho is a potential biomarker for renal injury; (3)
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Figure 3 |Klotho and neutrophil gelatinase-associated lipocalin (NGAL) in blood and kidney in acute kidney injury (AKI) rats from
1 to 24h. (a) Representative immunoblot for immunoprecipitated (IP) Klotho (upper panel) in blood of AKI and Sham rats at 1, 3, 5, and 24 h
post-reperfusion (three rats at each time point); immunoglobulin G (IgG) heavy chain (IgG-HC) band is shown for IP control. One hundred ml
of heparinized blood was immunoprecipitated with rabbit anti-human Klotho antibody (KMDC) and immunoblotted for Klotho protein with
rat anti-Klotho antibody (KM2076). (b) Representative immunoblot for Klotho in total kidney lysates of AKI and Sham rats at 1, 3, 5, and 24 h
post-reperfusion (three rats at each time point). Thirty mg of protein were loaded in each lane and subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) followed by immoblotting with rat anti-Klotho antibodies. (c) Representative immunoblot for NGAL in blood of AKI
and Sham rats at 1, 3, 5, 24 h post-reperfusion (three rats at each time point). Four ml of heparinized blood from rats were mixed with
Laemle’s buffer and subjected to immunoblot with goat anti-NGAL antibody (1/200 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). (d) Representative immunoblot for NGAL in total kidney lysates of AKI and Sham rats at 1, 3, 5, and 24 h post-reperfusion (three rats at
each time point). Thirty mg of protein were loaded in each lane and subjected to SDS-PAGE followed by immoblotting with goat anti-NGAL
antibody.
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determine whether Klotho has any pathogenic role in renal
injury or protection from IRI and if so, replacement of
Klotho can be a therapeutic option. We showed that AKI is a
state of acute Klotho deficiency in the blood, urine, and
kidney. Human urine Klotho measurements also support this
notion. In addition to being a biomarker for renal injury,
Klotho levels correlated with resilience to kidney damage in
AKI. This is consistent with the previous data indicating that
forced expression of exogenous Klotho by an adenoviral
vector reduced apoptosis and kidney damage in IRI.22,24 A
single bolus injection of recombinant Klotho protein is
effective in ameliorating AKI even when administered after
the insult. This study has identified Klotho protein as a
potential biomarker and therapeutic agent for AKI.
Clinical diagnostic potential
The current use of plasma Cr suffers from the reliance on
accumulation of Cr in the blood after reduction of
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Figure 4 |Klotho protein expression in acute kidney injury (AKI) mice with different genetic background. (a) Representative
immunoblot for Klotho in total kidney lysate from four mouse kidneys each group at day 2 post-ischemia–reperfusion injury (IRI) (upper
panel). Thirty mg of protein was immunoblotted for Klotho protein with rat anti-Klotho antibody. Lower panel is a summary of densitometric
quantification of the data. (b) Representative fluorescent immunohistochemistry for Klotho in kidney sections of four mice in each group at
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glomerular filtration and hence is notoriously slow. More-
over, renal hypoperfusion without true parenchymal damage
(prerenal failure) can sometimes lead to a syndrome very
similar to that of AKI and challenges distinction even by the
most seasoned expert clinicians. Several biomarkers of AKI
are being investigated with the most evidence centered on
kidney injury molecule-1 (Kim-1)29 and NGAL.25–27 Kim-1
expression in kidney and excretion in urine are sensitive and
specific for kidney injury as well as predictors of outcome.30
The elevation of NGAL in the blood, urine, and kidney is an
indicator of active kidney damage25–27,31 and is also
associated with severity of kidney damage.32,33 NGAL in
kidney is induced early post-IRI (Figure 3c and d and
Supplementary Figure S2D online).34 Conditions that
activate leukocytes such as cerebrovascular ischemia,35
inflammation,36 and cancer37 also upregulate NGAL in
plasma, urine, and local tissues. Kim-1 is a more specific
marker for kidney injury, but its upregulation in IRI-induced
AKI rodent model occurs at 9 h post-IRI.29 This study
indicates that the decreased Klotho is detectable 5 h post-IRI
in AKI rodent model. The time course of Klotho decrease
remains to be confirmed in human clinical studies. The
exploration of Klotho specificity in diagnosis of AKI is
beyond the scope of this study.
Clinical therapeutic potential
Currently, supportive care including renal replacement
therapy remains the core of clinical management.1 Replace-
ment therapy is unlikely to significantly affect the disease
course of AKI per se and intensive therapy appeared not to
consistently or dramatically increase survival rate or improve
long-term outcome.5 Our studies suggest that Klotho may
have a role in both reducing kidney damage and promoting
kidney recovery. Klotho deficiency worsens ischemia–reper-
fusion-induced injury in hindlimbs and overexpressing
Klotho protein attenuates IRI-induced tissue damage
through decreasing apoptosis,22,24 or promotes tissue regen-
eration through angiogenesis.38,39 These studies increased
Klotho level through either genetic manipulation or viral-
based Klotho delivery system, and none of them used Klotho
replacement. As transgenic expression can have a myriad of
secondary effects, we showed that protection can be
conferred by giving recombinant Klotho thus raising the
potential for clinical use. At least in the rodent model, there
appears to be a time-dependent efficacy of exogenous Klotho
replacement and that early Klotho supplementation may be
critical for AKI treatment. Klotho may function more
efficiently as a preventive than a repair agent.
Mechanism of reduction of Klotho expression in AKI and
Klotho’s renoprotective action
IRI leads to rapid and pronounced reduction of Klotho
mRNA and protein in kidney of animals. But the mechanism
of how Klotho is downregulated is not known. One in vitro
study showed that oxidative stress decreases Klotho mRNA
and protein in a cultured cell line.40 We showed that Klotho
reduction in vivo takes place only 3 h post-IRI. It was
suggested that tumor necrosis factor and interferon-g in mice
with colitis reduces renal Klotho mRNA and protein through
activation and induction of nitric oxide production.41 But
whether an increase in tumor necrosis factor and interferon-g
in AKI42 results in Klotho downregulation is not known.
Klotho is expressed prominently in renal distal tubules8
and to a lesser extent in renal proximal tubules.17 Although
the transmembrane form of Klotho functions as a coreceptor
for FGF23 signaling,10 the extracellular domain of Klotho is
released43,44 into blood, urine, and the cerebrospinal
fluid15,16,19 and can potentially function as an endocrine
factor to affect distant organs. We found higher blood FGF23
and inorganic phosphate in Klþ / mice compared with WT
and Tg-Kl mice (Supplementary Figure S7 online). IRI signi-
ficantly increase blood inorganic phosphate compared with
Sham in all groups, except in Tg-Kl animals. Of note is that IRI
did not significantly alter blood levels of FGF23, except in the
Klþ / mice, where IRI slightly suppressed FGF23. Therefore,
unlike chronic states of Klotho deficiency, the acute Klotho
deficit in AKI is not associated with high FGF23.
In an immune-mediated glomerulonephritis model,
increasing Klotho improved renal function and reduced
mitochondrial DNA fragmentation, superoxide anion gen-
eration, lipid peroxidation, and apoptosis, suggesting that
Klotho may ameliorate mitochondrial oxidative stress.21
Klotho also inhibits apoptosis and senescence in vascular
endothelial cells,45 and upregulation of heat-shock protein-70
by Klotho is associated with inhibition of apoptosis.24
Another possible mechanism whereby Klotho deficiency
during AKI worsens kidney damage may be abnormal
activation of calpain and degradation of cytoskeletal
elements.46 The fact that soluble Klotho significantly
increases NGAL protein and mRNA in the kidney of Sham
Table 4 | Kidney function in AKI mice of Kl+/ group
WT Kl+/
Sham AKI Sham AKI
Cr (mg/dl) 0.13±0.03 0.29±0.06* 0.17±0.10 0.33±0.05**
ClCr (ml/min per g) 12.80±2.01 4.84±1.63
** 15.50±1.80 3.34±0.12*,#
Abbreviations: AKI, acute kidney injury; Cr, creatinine; ClCr, clearance creatinine; WT,
wild type.
Data at day 2 are represented as mean±s.e.m.; n=8. Significant differences were
accepted when *Po0.05, **Po0.01 vs Sham; #Po0.05 vs WT AKI by analysis of
variance followed by Student–Newman–Keuls test.
Table 5 | Kidney function in AKI mice of Tg-Kl group
WT Tg-Kl
Sham AKI Sham AKI
Cr (mg/dl) 0.27±0.01 0.48±0.01* 0.33±0.03y 0.35±0.04*,#
ClCr (ml/min per g) 14.23±2.14 5.65±0.57
** 9.68±3.19y 7.49±0.50*,#
Abbreviations: AKI, acute kidney injury; Cr, creatinine; ClCr, clearance creatinine; WT,
wild type.
Data at day 2 are represented as mean±s.e.m.; n=8. Significant differences were
accepted when *Po0.05, **Po0.01 vs Sham; #Po0.05 vs WT AKI; yPo0.05 vs WT
Sham by analysis of variance followed by Student–Newman–Keuls test.
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rats suggests that Klotho activates NGAL. NGAL has a
protective role in ischemic kidney injury.28,47 We proposed that
the upregulation of NGAL by Klotho is one mechanism of
renoprotection conferred by Klotho. The full spectrum of
mechanisms of Klotho’s protective effect remains to be studied.
MATERIALS AND METHODS
Human study
The study was approved by the Institutional Review Board at the
University of Texas (UT) Southwestern Medical Center. The study
population consisted of 17 AKI patients recruited randomly in
Parkland Memorial Hospital affiliated with UT Southwestern. The
diagnosis was based on 50% acute rise in blood Cr or to a
concentration above 2.0 mg/dl from baseline.1,2 Normal control
consisted of 14 healthy volunteers with no known health problems
and on no medications, enrolled from the staff and students at the
UT Southwestern Medical Center (Tables 2 and 3). All subjects
gave informed consent. For measurement of urinary Klotho
protein, 4 ml fresh urine was concentrated to 0.2 ml through
Amicon Ultra-4 filters with 100 kDa cutoff (Millipore, Billerica, MA,
USA), and immediately mixed with Laemmli sample buffer and
stored at 80 1C. Urine samples with identical Cr content along
with recombinant murine Klotho (standard curve) protein of
known concentration were subject to immunoblot and specific
signals based on bands on films were obtained with free Image J
program (NIH, Washington DC, USA).
Animal models
Male Spraque–Dawley rats (250–350 g) were used for Experiments 1
and 3. Male mice (30–40 g; genetic background for Tg-Kl
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Figure 5 |Klotho administration post-ischemia–reperfusion injury (IRI) in acute kidney injury (AKI) rats. AKI and Sham rats treated
with Klotho (Kl) or vehicle (Veh) 30min post-reperfusion were killed at 0, 1, 2, and 7 days after IRI and blood and urine were collected for
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expressed as mean±s.e.m. (n¼ 4) in each group. Statistical significance was analyzed by analysis of variance (ANOVA) followed by
Student–Newman–Keuls test, for data presented in a–e and significant differences were accepted when *Po0.05, **Po0.01 vs Sham-vehicle
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mice¼mixture of C57BL/6J and 129, and for Klþ / mice¼mixture
of C57BL/6J and C3H/J) were used for Experiment 2. Lines included
the following: (1) transgenic mice overexpressing Klotho, EFmKL46
(Tg-Kl);8–9 and (2) heterozygous Klotho-deficient mice (Klþ /).8
WT littermates were generated during crossbreeding for Tg-Kl and
Klþ / mice. The age of Klþ /, Tg-Kl, and WT mice ranged from 12
to 16 weeks. All animal work was conducted following the Guide for
the Care and Use of Laboratory Animals by The National Institutes
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significant differences were accepted when Po0.05 or less between two groups. Immunoblot for Klotho protein in total kidney lysate from
rats on days 1, 2, and 7. Representative immunoblot for Klotho and b-actin in total kidney lysate of six rats in each group (c, upper panel). A
summary of densitometric quantification of all samples is shown in lower panel. Results are expressed as mean±s.e.m. of six rats in each
group. Statistical significance was assessed by ANOVA followed by Student–Newman–Keuls test, and significant differences were accepted
when *Po0.05, **Po0.01 vs Sham-vehicle rats; #Po0.05; ##Po0.01 vs AKI-vehicle rats; yPo0.05,yyPo0.01 vs Sham-Klotho rats. Infrared
dye-labeled Klotho (IR-Kl) in blood and urine of Sham or AKI rats (d). Rats were intravenously injected once with IR-Kl and 4 ml of plasma at 5,
10, 30, 60min, and at 24 and 48 h post-injection and of fresh spot urine at 20min and 24 and 48 h post-injection were collected and
fractionated on 7.5% SDS-polyacrylamide gel electrophoresis and scanned by Odyssey Infrared Imaging System (Lincoln, NE, USA).
IR-Klotho in the kidneys of Sham and AKI rats (e): After a single bonus intravenous injection of IR-Klotho, rats were killed at the indicated
time points for examination of labeled IR-Klotho in kidneys. Four mm cryosections of non-fixed kidneys were prepared and scanned directly
using Odyssey Infrared Imaging System. A, AKI; S, Sham rats.
Kidney International (2010) 78, 1240–1251 1249
M-C Hu et al.: Klotho and acute ischemic renal injury o r ig ina l a r t i c l e
of Health and was approved by the Institutional Animal Care and
Use Committee at the UT Southwestern. AKI model was generated
using bilateral renal IRI.48 Under anesthesia, renal arteries were
clamped with arterial clips (30 min Experiment 2; or 40 min
Experiments 1 and 3). After clips were removed, the kidneys were
observed for 5 min to ensure reperfusion. Sham animals underwent
laparotomy of the same duration without arterial clamping. At
predetermined times after reperfusion, 24-h urine was collected.
Under anesthesia, blood was drawn and kidneys were harvested,
instantly snap-frozen in liquid nitrogen, and stored at 80 1C for
further processing. Plasma and urine chemistry of animals were
analyzed using a Vitros Chemistry Analyzer (Ortho-Clinical
Diagnosis, Rochester, NY, USA).
Experiment 1. Sprague–Dawley rats were randomly assigned to
Sham or AKI. Twenty-four-hour urine samples and blood were
collected at 1, 3, 5 h and on days 1, 2, and 7 after surgery,
respectively.
Experiment 2. Klþ / mice, Tg-Kl mice, and their WT
littermates were randomly divided into Sham and AKI for each
genotype. Twenty-four-hour urine samples were collected and blood
samples were drawn on day 2.
Experiment 3. To study the therapeutic effect of Klotho
administration post-IRI on AKI, Sprague–Dawley rats were
randomly divided into either Sham or AKI, and the animals in
each group were randomly allocated into vehicle or Klotho
treatment. Animals in the Klotho group received one bonus
intraperitoneal injection of recombinant mouse Klotho protein
(0.01 mg/kg body weight) 30 or 60 min after reperfusion; rats in
vehicle group received the same volume of Klotho buffer (150 mM
NaCl and 10 mM HEPES pH 7.4). Twenty-four-hour urine and
blood were collected on days 1, 2, and 7 after surgery.
See Supplementary Information for detailed methods on kidney
histology and histopathology, immunohistochemistry, immunoblot,
real-time reverse transcription-PCR, clearance study on labeled
Klotho in normal rats, blood FGF23 determination using enzyme-
linked immunosorbent assay.
Statistical analysis
Data are expressed as the means±s.e.m. (n¼ 3 or more unless
indicated otherwise). Statistical analysis was performed using
Student’s unpaired or paired t-test, or analysis of variance followed
by all pairwise multiple comparison procedures using Student–-
Newman–Keuls test when appropriate. A value of Pp0.05 was
considered statistically significant.
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